Terms: = Leukemia AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Treatment
1461 results:
1. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract] [Full Text] [Related]
2. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan.
Edahiro Y; Ochiai T; Hashimoto Y; Ichii M; Okatani T; Omura H; Nakajima K; Sasaki M; Ando J; Takaku T; Koike M; Izumiyama K; Hiraga J; Yano T; Usuki K; Ohtsuka E; Yokoyama K; Oyake T; Takahashi N; Nishida T; Nakao T; Fukuda Y; Akasaka T; Mugitani A; Ando M; Komatsu N
Hematology; 2024 Dec; 29(1):2340149. PubMed ID: 38626148
[TBL] [Abstract] [Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study.
Guo W; Zhao L; Huang W; Chen J; Zhong T; Yan S; Hu W; Zeng F; Peng C; Yan H
Cardiovasc Diabetol; 2024 Apr; 23(1):118. PubMed ID: 38566143
[TBL] [Abstract] [Full Text] [Related]
4. Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.
Franke GN; Loewe G; Reiser M; Linde H; Josting A; von der Heyde E; Platzbecker U; Weide R; Tesch H; Nusch A; Dengler J; Jentsch-Ullrich K
Ann Hematol; 2024 May; 103(5):1569-1575. PubMed ID: 38472361
[TBL] [Abstract] [Full Text] [Related]
5. Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia.
de Tute R; Counsell N; Clifton-Hadley L; D'Sa S; Pratt G; Campbell G; Campbell L; Sadler R; Townsend W; Popova B; Smith P; Schofield O; Owen R; Auer R
Leukemia; 2024 Apr; 38(4):822-828. PubMed ID: 38409530
[TBL] [Abstract] [Full Text] [Related]
6. Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic leukemia.
Samardžić-Predojević J; Đurđević-Banjac B; Malčić-Zanić D
Acta Med Acad; 2023 Dec; 52(3):153-160. PubMed ID: 38407081
[TBL] [Abstract] [Full Text] [Related]
7. [Short-term Effect of Venetoclax Combined with Azacitidine and "7+3" Regimen in the treatment of Newly Diagnosed Elder Patients with Acute Myeloid leukemia].
Liu XX; Wen XL; Li RQ; Zhang XL; Zhang TB; Dong CX; Wang MF; Zhang JH; Yang LH; Zhang RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):96-103. PubMed ID: 38387906
[TBL] [Abstract] [Full Text] [Related]
8. Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
Zhang T; Zhang Y; Zhou M; Zhang Z; Bao X; Wen L; Feng Y; Li X; Zhai M; Liu X; Zeng Z; Wu X; Chen S
Br J Haematol; 2024 Apr; 204(4):1402-1413. PubMed ID: 38327115
[TBL] [Abstract] [Full Text] [Related]
9. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Jabbour E; Zugmaier G; Agrawal V; Martínez-Sánchez P; Rifón Roca JJ; Cassaday RD; Böll B; Rijneveld A; Abdul-Hay M; Huguet F; Cluzeau T; Díaz MT; Vucinic V; González-Campos J; Rambaldi A; Schwartz S; Berthon C; Hernández-Rivas JM; Gordon PR; Brüggemann M; Hamidi A; Chen Y; Wong HL; Panwar B; Katlinskaya Y; Markovic A; Kantarjian H
Am J Hematol; 2024 Apr; 99(4):586-595. PubMed ID: 38317420
[TBL] [Abstract] [Full Text] [Related]
10. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
11. Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid leukemia via Circulating Tumor DNA.
Liu LP; Zong SY; Zhang AL; Ren YY; Qi BQ; Chang LX; Yang WY; Chen XJ; Chen YM; Zhang L; Zou Y; Guo Y; Zhang YC; Ruan M; Zhu XF
Clin Cancer Res; 2024 Mar; 30(6):1143-1151. PubMed ID: 38170574
[TBL] [Abstract] [Full Text] [Related]
12. Suppression of DNMT1 combined with ATM or ATR inhibitor as a therapeutic combination of acute myeloid leukemia.
Liu L; Hu X; Feng J; Lei A; Huang S; Liu X; Liu H; Luo L; Yao W
Anticancer Drugs; 2024 Mar; 35(3):251-262. PubMed ID: 38164802
[TBL] [Abstract] [Full Text] [Related]
13. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
[TBL] [Abstract] [Full Text] [Related]
14. Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies.
Asadi M; Kiani R; Razban V; Faraji SN; Ahmadi A; Fallahi J; Ramezani A; Erfani N
Iran J Immunol; 2023 Dec; 20(4):410-426. PubMed ID: 38102941
[TBL] [Abstract] [Full Text] [Related]
15. Phthalimide-tethered isatins as novel poly(ADP-ribose) polymerase inhibitors: Design, synthesis, biological evaluations, and molecular modeling investigations.
El Hassab MA; El-Hafeez AAA; Almahli H; Elsayed ZM; Eldehna WM; Hassan GS; Abou-Seri SM
Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300599. PubMed ID: 38100160
[TBL] [Abstract] [Full Text] [Related]
16. Chronic Lymphocytic leukemia Therapy Guided by Measurable Residual Disease.
Munir T; Cairns DA; Bloor A; Allsup D; Cwynarski K; Pettitt A; Paneesha S; Fox CP; Eyre TA; Forconi F; Elmusharaf N; Kennedy B; Gribben J; Pemberton N; Sheehy O; Preston G; Schuh A; Walewska R; Duley L; Howard D; Hockaday A; Jackson S; Greatorex N; Girvan S; Bell S; Brown JM; Webster N; Dalal S; de Tute R; Rawstron A; Patten PEM; Hillmen P;
N Engl J Med; 2024 Jan; 390(4):326-337. PubMed ID: 38078508
[TBL] [Abstract] [Full Text] [Related]
17. [Clinical Analysis of Infants with Acute Lymphoblastic leukemia (18 cases)].
Li KL; Xiong H; Li H; Wang Z; Chen Z; Yang L; Lu WJ; Qi SS; Sun M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1670-1675. PubMed ID: 38071044
[TBL] [Abstract] [Full Text] [Related]
18. Usefulness Of Sofosbuvir And Daclatasvir Combination In The treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital.
Imam U; Parkash A; Daryani N; Mumtaz F
J Pak Med Assoc; 2023 Nov; 73(11):2183-2188. PubMed ID: 38013525
[TBL] [Abstract] [Full Text] [Related]
19. Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study.
Yu S; Zhang Y; Yu G; Wang Y; Shao R; Du X; Xu N; Lin D; Zhao W; Zhang X; Xiao J; Sun Z; Deng L; Liang X; Zhang H; Guo Z; Dai M; Shi P; Huang F; Fan Z; Liu Q; Lin R; Jiang X; Xuan L; Liu Q; Jin H
J Intern Med; 2024 Feb; 295(2):216-228. PubMed ID: 37899297
[TBL] [Abstract] [Full Text] [Related]
20. Leptin Increase During Dexamethasone and Its Association With Hunger and Fat in Pediatric Acute Lymphoblastic leukemia.
van Hulst AM; Verwaaijen EJ; van den Berg SAA; van Litsenburg RRL; Grootenhuis MA; Fiocco M; Neggers SJCMM; van den Heuvel-Eibrink MM; van den Akker ELT
J Clin Endocrinol Metab; 2024 Feb; 109(3):631-640. PubMed ID: 37878899
[TBL] [Abstract] [Full Text] [Related]
[Next]